Major depressive disorder (MDD) and other mental health issues pose a substantial burden on the workforce. Approximately half a million Canadians will not be at work in any week because of a mental health disorder, and more than twice that number will work at a reduced level of productivity (presenteeism). Although it is important to determine whether work plays a role in a mental health condition, at initial presentation, patients should be diagnosed and treated per appropriate clinical guidelines. However, it is also important for patient care to determine the various causes or triggers including work-related factors. Clearly identifying the stressors associated with the mental health disorder can help clinicians to assess functional limitations, develop an appropriate care plan, and interact more effectively with worker's compensation and disability programs, as well as employers. There is currently no widely accepted tool to definitively identify MDD as work-related, but the presence of certain patient and work characteristics may help. This paper seeks to review the evidence specific to depression in the workplace, and provide practical tips to help clinicians to identify and treat work-related MDD, as well as navigate disability issues., Competing Interests: PC: Support for the present manuscript from Abbvie, Janssen, Lundbeck, Otsuka, Takeda, and Telus; and consulting fees and payment or honoraria from Abbvie, Elvium, Janssen, Lundbeck, Otsuka, and Takeda. AB: Consulting fees from RBC Insurance, WSIB (Ontario), and the Liquor Control Board of Ontario (LCBO); honoraria for speaking engagement from Osgoode School of Law; payment for expert testimony from the Canadian Medical Malpractice Agency; participation on a data safety monitoring board or advisory board for Lundbeck; and an unpaid leadership or fiduciary role with the Cunningham Society. SB: Consulting fees from Abbvie and Otsuka; payment for lectures or educational events from Janssen-Ortho, Lundbeck, Takeda, Otsuka, and Abbvie; travel support for meeting attendance from Otsuka; and board membership for the Saskatchewan chapter of the Canadian Psychiatric Association. GA: Consulting fees from Abbvie, Allergan, Amgen, Astellas Pharma, AstraZeneca, CCRN, CCPDHM/CHRC, Esai, Galderma, Janssen, Lundbeck, MD Briefcase, MedPlan, Novo Nordisk, Otsuka, Purdue, Takeda, The Academy, Valeant, and Novartis; payment or honoraria for speakers bureaus from Elvium, Sunovion, Esai, Janssen, Takeda, Lundbeck, Valeant, Allergan, Otsuka; and board membership (volunteer) for the Canadian ADHD Resource Alliance (CADDRA). MC: Institutional research grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada (SSHRC), Fonds de recherche du Québec (FRQSC), and funding of a research chair position at the Institut Universitaire en Santé Mentale de Montréal (IUSMM); payment or honoraria from IGF Québec, Les Affaires, Canadian Pension and Benefits Institute (CPBI-ICRA), Swiss Society of Social Psychiatry, University of Montréal, Colloque Insertion Vaud 2022, and AMPQ. DD: Grants or contracts from SSHRC; book royalties from Guilford Press, American Psychological Association, Elsevier, and Pearson; consulting fees from Otsuka; payment or honoraria for presentation from McGill University; board membership for Mental Health Research Canada and the International Association of Applied Psychology; editorial board membership for Clinical Psychology: Science and Practice, Canadian Psychology, Cognitive Therapy and Research, and Canadian Journal of Behavioral Science. JeH: Consulting fees from Otsuka, HLS, Amgen, Pfizer, Eisai, Eli-Lilly, Janssen, Lundbeck, Novo-Nordisk, Valeo, Abbvie, Elvium, and Bausch; and payment or honoraria for speakers bureaus from Pfizer, Amgen, Abbvie, GSK, Bayer, Boehringer, Eli-Lilly, Purdue, Bausch, Allergan, AstraZeneca, Novartis, Lundbeck, Novo-Nordisk, Janssen, Eisai, HLS, Otsuka, Sunovion, MDBriefcase, Liv, MedPlan, Master Clinician Alliance, Academy, Bridge, PeerVoice, Seacourses, Thrombosis Canada, Meducom, Antibody, CHRC, CTC, STA, CCRN, CPD Network, Telus Health, EOCI, AgenceUnik, and Pri-Med. JoH: Employment with Metis Cognition Ltd. Royalties or licenses from Metis Cognition Ltd. for BASIC; consulting fees (paid to Metis Cognition Ltd) from Actinogen, Alzecure, ADvantage, AstraZeneca, Athira Therapeutics, Axoltis, Axon Neuroscience, Bial Biotech, Biogen Idec, Boehringer Ingelheim, Brands2Life, Cerecin, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EcoR1, Eisai, EIP Pharma, Eli Lilly, EQT Life, Games for Health EU, Heptares, Ki-Elements, Lundbeck, Lysosome Therapeutics, MyCognition, Neurotrack, NHS, Novartis, Novo Nordisk, Nutricia, Recognify, Remynd, Roche, Rodin Therapeutics, Signant Health, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics, Winterlight Labs, Stoke Therapeutics, Alto Pharma; payment or honoraria (paid to Metis Cognition Ltd) for presentations from Roche; travel support for meeting attendance (paid to Metis Cognition Ltd) from Roche and Biogen; patent for MyCognition; participation on a data safety monitoring board or advisory board for Esai; and stock or stock options from Neurotrack. MK: Grants or contracts from Abbvie, AstraZeneca, Biotics, Canopy, Eisai, Janssen, Lundbeck, Otsuka, Shire, Takeda, and Biohaven; consulting fees from Janssen, Eli Lily, Novartis, Merck, Otsuka, Pfizer, Purdue, Sante Cannabis, Sunovion, Takeda, and Tilray; payment or honoraria from Abbvie, Biron, Alefia Cannabis, Allergan, Bausch Health, Canopy, Eisai, Elvium, Empower Cannabis, Lundbeck; participation on a data safety monitoring board or advisory board for Abbvie, Lundbeck, Biron, Elsai, and Ironshore; board membership for ASPARD; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Biron. RM: Grants from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; consulting fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences; and is CEO of Braxia Scientific Corp. YL: Institutional grant support from MITACS and Chokka Center for Integrative Health. KN: Institutional grants from the Dutch Social Security Agency, Netherlands Organization for Health Research and Development, and the Dutch Ministry of Education. CD: Consulting fees from Modern Health. Funding Statement: This study received funding via arms-length grants to the Workplace Mental Health Network from Allergan Inc., Lundbeck Canada Inc., Janssen Inc., Otsuka Canada Pharmaceutical Inc. and Telus Mobility. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication., (Copyright © 2023 Chokka, Bender, Brennan, Ahmed, Corbière, Dozois, Habert, Harrison, Katzman, McIntyre, Liu, Nieuwenhuijsen and Dewa.)